We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam and Cubist Collaborates to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection

News   Jan 12, 2009

 
Alnylam and Cubist Collaborates to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection
 
 
 

RELATED ARTICLES

Temperature-stable Tuberculosis Vaccine Enters Clinical Testing

News

Vaccinations have begun in a Phase 1 human clinical trial testing a freeze-dried, temperature-stable formulation of an experimental tuberculosis vaccine candidate.

READ MORE

Artificially Produced Cells Communicate with Each Other

News

The cells, separated by fatty membranes, exchange small chemical signaling molecules to trigger more complex reactions, such as the production of RNA and other proteins.

READ MORE

Placental Mitochondria Adapt When Mothers Have Poor Diets or Low Oxygen

News

Using mice to model conditions in the womb, Cambridge researchers have provided new insights on how the placenta regulates how much oxygen and nutrients it transports to babies during challenging pregnancies.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE